These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28732453)

  • 41. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
    Yildiz I; Sen F; Basaran M; Ekenel M; Agaoglu F; Darendeliler E; Tunc HM; Ozcan F; Bavbek S
    Jpn J Clin Oncol; 2011 Dec; 41(12):1380-7. PubMed ID: 22013228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hand-Foot Syndrome and Progression-Free Survival in Patients Treated with Sunitinib for Metastatic Clear Cell Renal Cell Carcinoma.
    Kucharz J; Budnik M; Dumnicka P; Pastuszczak M; Kuśnierz-Cabala B; Demkow T; Popko K; Wiechno P
    Adv Exp Med Biol; 2019; 1133():35-40. PubMed ID: 30701441
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of Single Nucleotide Polymorphisms in STAT3 with Hand-Foot Skin Reactions in Patients with Metastatic Renal Cell Carcinoma Treated with Multiple Tyrosine Kinase Inhibitors: A Retrospective Analysis in Japanese Patients.
    Yamamoto K; Shinomiya K; Ioroi T; Hirata S; Harada K; Suno M; Nishioka T; Kume M; Makimoto H; Nakagawa T; Hirano T; Bito T; Nishigori C; Miyake H; Fujisawa M; Hirai M
    Target Oncol; 2016 Feb; 11(1):93-9. PubMed ID: 26300443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
    Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
    Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Side effect management of tyrosine kinase inhibitors in urology : Hypertension].
    Sikic D; Meidenbauer N; Lieb V; Keck B
    Urologe A; 2016 Jul; 55(7):952-5. PubMed ID: 27146871
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
    Akaza H; Oya M; Iijima M; Hyodo I; Gemma A; Itoh H; Adachi M; Okayama Y; Sunaya T; Inuyama L
    Jpn J Clin Oncol; 2015 Oct; 45(10):953-62. PubMed ID: 26206897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Managing adverse events associated with sorafenib in renal cell carcinoma.
    Edmonds K; Spencer-Shaw A
    Br J Nurs; 2010 Jan 14-27; 19(1):58-60. PubMed ID: 20081715
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
    Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
    Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
    Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
    Walko CM; Grande C
    Semin Oncol; 2014 Feb; 41 Suppl 2():S17-28. PubMed ID: 24576655
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypertension Induced by Tyrosine-Kinase Inhibitors for the Treatment of Renal Cell Carcinoma in Hemodialysis Patients: A Single-Center Experience and Review of the Literature.
    Nakai K; Fujii H; Kono K; Goto S; Nishi S
    Ther Apher Dial; 2017 Aug; 21(4):320-325. PubMed ID: 28544682
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.
    Kato H; Sassa N; Miyazaki M; Takeuchi M; Asai M; Iwai A; Noda Y; Gotoh M; Yamada K
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):855-62. PubMed ID: 27586968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS; Manchen B
    Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors.
    Iacovelli R; Verri E; Cossu Rocca M; Aurilio G; Cullurà D; de Cobelli O; Nolè F
    Anticancer Drugs; 2017 Feb; 28(2):206-212. PubMed ID: 27754995
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of Efficacy, Safety, and Quality of Life of 124 Patients Treated With Axitinib as Second-Line Therapy for Metastatic Renal-Cell Carcinoma: Experience in Real-World Clinical Practice in Japan.
    Miyake H; Harada KI; Ozono S; Fujisawa M
    Clin Genitourin Cancer; 2017 Feb; 15(1):122-128. PubMed ID: 27473522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
    van der Veldt AA; van den Eertwegh AJ; Boven E
    Ned Tijdschr Geneeskd; 2007 May; 151(20):1142-7. PubMed ID: 17557672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.